Filament Health
PEX010 · Botanical Psilocybin Extract · Opioid Use Disorder
Company Overview
Filament Health is a drug development company working with naturally-derived psychedelic medicines. Their lead program PEX010 is a standardized botanical psilocybin extract pursuing the FDA's botanical drug development pathway. ⚠ ACQUIRED: In 2026 Filament was acquired by Red Light Holland (CSE: TRIP / OTCQB: TRUFF) via a plan of arrangement (final court order April 29, 2026) and is now a wholly-owned subsidiary — the FLHLF ticker is effectively defunct as a standalone listing. Under new ownership, PEX010 has advanced through investigator-initiated studies and secured Europe's first psilocybin compassionate-use approval (June 2026).
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
PEX010 Botanical psilocybin extract (standardized natural extraction) | Phase 2 (Investigator-Initiated) | Opioid Use Disorder |
FH-202 Botanical DMT extract | Preclinical | Depression |
Key Financials
- Cash Position
- $337,082
- Burn Rate
- Under $1M/quarter
- Last Reported
- Q4 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- H2 2026PEX010 feasibility study data readout (OUD)Clinical
Recent News
- 2026-05Red Light Holland completes acquisition of Filament Health; PEX010 continues under new ownership
- 2025-05Filament Health delisted from Cboe Canada; shares move to OTC Pink amid going concern disclosure
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 650+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-07-21. Always consult official company filings and a qualified financial advisor before making investment decisions.